Lundbeck and Prexton Therapeutics BV (Prexton) have signed an agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones.   Because of the acquisition, Lundbeck will obtain global rights for Prexton’s foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) in...